We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Pfizer Adds Expertise in Biologics With Wyeth Acquisition
Pfizer Adds Expertise in Biologics With Wyeth Acquisition
February 2, 2009
Pfizer’s $68 billion purchase of Wyeth accomplishes its goal of entering the biotech market by not only gaining access to Enbrel, a tumor necrosis factor inhibitor antibody, but by adding a “world-class” manufacturing operation that could be used to produce biosimilars.